Statera Biopharma, Inc. STAB

STAB Company Overview

Statera Biopharma, Inc. (NASDAQ previously: STAB) was a clinical-stage biopharmaceutical company focused on the development of immunotherapy and immune restoration technologies for autoimmune diseases and cancer. Public filings and historical investor materials describe the company as operating within the biotechnology and biopharmaceutical industries, with a primary emphasis on therapies designed to modulate immune system responses through cytokine-based and immunomodulatory approaches.

The company evolved through a series of restructurings and strategic transitions, including operating previously under the name Cytocom, Inc. before rebranding as Statera Biopharma. Its business model centered on research and development rather than commercial product sales, meaning its primary financial activity historically came from capital raising, licensing activity, and strategic transactions rather than recurring operating revenue. Public disclosures indicate the company sought differentiation through platform-based immunology programs targeting both inflammatory and oncology indications. Data regarding later-stage commercialization progress and long-term operating continuity is inconclusive based on available public sources.